Brandon Smaglo

A Phase 1 Study of Patient-Derived Multi-Tumor Associated Antigen Specific T Cells (MT-601) Administered to Patients with Metastatic Pancreatic Cancer Following Frontline FOLFIRINOX

National Cancer Institute · R44

PI · $1.3M · Marker Therapeutics, Inc.

A Phase 1 Trial Of Safety And Initial Efficacy Of Vagal Nerve Blockade For Cancer-Induced Cachexia In Patients With Metastatic Pancreatic Adenocarcinoma

Principal investigator · Not yet recruiting · Phase 1

M.D. Anderson Cancer Center

A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma

Principal investigator · Active not recruiting · Phase 1

M.D. Anderson Cancer Center

Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer

Principal investigator · Active not recruiting · Phase 2

M.D. Anderson Cancer Center

iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation

Principal investigator · Recruiting · Phase 1, Phase 2

M.D. Anderson Cancer Center